The overall response rates to afatinib and neratinib in NSCLC patients with G719X mutations were 77.8% and 75%, respectively, with mPFS of 13.8 months and 12.1 months and mOS of 26.9 months (9, 16), which were similar to those for classic EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.